Dr. Song discusses the latest safety data on topical and oral JAK inhibitors for patients with atopic dermatitis.

Dr. Guttman-Yassky discusses a post-hoc analysis that evaluated the efficacy of upadacitinib after 140 weeks in patients with atopic dermatitis. Reference: Butler D, et al....
PLAY